Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 1

Conditions

Breast Neoplasms 24Hereditary Sensory and Autonomic Neuropathies 6Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Ovarian Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Head and Neck Neoplasms 2Advanced Breast Cancer 2Triple Negative Breast Neoplasms 1Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein 1Pre-menopausal Breast Cancer 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Kidney Neoplasms 1Hyperglycemia 1HER2-positive Metastatic Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Advanced or Metastatic ER+ Breast Cancer 1Advanced and Selected Solid Tumors 1Advanced Solid Tumors With an Alteration of the PIK3CA Gene 1Advanced Solid Tumor 1Advanced HER2+Breast Cancer 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × Alpelisib × Clear all
NCT04729387 2026-06-04

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Novartis

Phase 3 Terminated
358 enrolled 19 charts
Gynecologic

Ovarian Neoplasms

NCT01708161 2018-09-13

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

Novartis

Phase 1/2 Terminated
47 enrolled 23 charts
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡